HERA-CD27L
/ Apogenix
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
May 26, 2019
HERA-CD27L, a true CD27 agonist, has superior activity over benchmark agonistic antibodies and induces T cell activation for potent anti-tumor immunity
(CIMT 2019)
- "As we have shown here, the hexavalent HERA-CD27L has superior activity compared to bivalent antibodies. Altogether, HERA-CD27L shows single-agent anti-tumor efficacy, is well tolerated by multiple relevant species and the lead candidate is currently ready for GMP cell line development."
IO Biomarker • PD(L)-1 Biomarker
April 05, 2019
HERA-CD27L, a true CD27 agonist, is a hexavalent CD27 ligand that enhances T cell activation and induces potent anti-tumor immunity
(AACR 2019)
- "As we have shown here, the hexavalent HERA-CD27L has superior activity compared to bivalent antibodies. Altogether, HERA-CD27L shows single-agent anti-tumor efficacy, is well tolerated by multiple relevant species and the lead candidate is currently ready for GMP cell line development."
IO Biomarker • PD(L)-1 Biomarker
February 21, 2019
Hexavalent Agonists Targeting the TNFR Superfamily for Cancer Immunotherapy
(TRICON 2019)
- "HERA compounds show single agent anti-tumor activity and provide exciting opportunities for combinatorial treatment. The presentation will focus on data obtained with HERA-CD40L, HERA-CD27L and HERA-GITRL."
1 to 3
Of
3
Go to page
1